Investigational drug · Phase 2
CEB-01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Resectable Pediatrics Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "CEB-01"
First trial start
2025
May 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CEB-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Resectable Pediatrics Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "CEB-01" as an intervention, largest first.
- CEB-01 in Pediatrics With Locally Resectable Abdominal TumorsActive, not recruiting
CEBIOTEXIndustry
NCT06986811 · 80 participants (planned) · Start May 6, 2025 · Primary completion May 2029
Drug: CEB-01 · For: Locally Resectable Pediatrics Tumors
Sites: Esplugues de Llobregat, Spain
- CEB-01 in Locally Resectable Pancreatic CancerActive, not recruiting
CEBIOTEXIndustry
NCT06538857 · 39 participants (planned) · Start Aug 20, 2024 · Primary completion Sep 2028
Drug: CEB-01 · For: Pancreatic Carcinoma
Sites: Barcelona, Spain; Madrid, Spain; Seville, Spain · 4 sites in all
CEBIOTEXIndustry
NCT04619056 · 21 participants · Start Jun 3, 2020 · Primary completion Nov 28, 2025
Drug: CEB-01 membrane loaded with SN-38 · For: Locally Advanced Soft Tissue Sarcoma; Recurrent Soft Tissue Sarcoma
Sites: Barcelona, Spain; Madrid, Spain; Valencia, Spain · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas.
Gonzalez JA, Sebio A, Martin-Broto J, et al. · Ann Surg Oncol 2026
- ASO Author Reflections: Preventing Local Recurrence After Surgery in Retroperitoneal Sarcoma with CEB-01, a SN-38-Releasing Membrane.
Sebio A, Gonzalez JA · Ann Surg Oncol 2026
- ASO Visual Abstract: First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas.
Gonzalez JA, Sebio A, Martin-Broto J, et al. · Ann Surg Oncol 2026
- CEB-01 membrane loaded with SN-38 for local post-resection control and metastasis reduction in preclinical pancreatic cancer models.
Ninou AH, Caruana P, Marti L, et al. · Drug Deliv Transl Res 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.